Oral ganciclovir and valganciclovir prophylaxis may prevent reactivation of non-β herpesviruses in cytomegalovirus (CMV) D+/R- solid organ transplant (SOT) patients

被引：0
|
作者：
Razonable, RR
Brown, RA
Humar, A
Covington, E
Alecock, E
Paya, CV
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Roche Prod Ltd, Med Sci, Welwyn Garden City AL7 3AY, Herts, England
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2004年 / 4卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
658
引用
收藏
页码：337 / 337
页数：1
相关论文
共 35 条
  • [1] A contrast in the incidence and prevalence of human herpesvirus (HHV)-6 and HHV-7 reactivation in cytomegalovirus (CMV) D+/R- solid organ transplant (SOT) patients receiving oral ganciclovir or valganciclovir prophylaxis
    Razonable, RR
    Brown, RA
    Humar, A
    Covington, E
    Alecock, E
    Paya, CV
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 534 - 535
  • [2] Human polyomavirus infection is common in cytomegalovirus (CMV) D+/R- solid organ transplant (SOT) patients
    Razonable, RR
    Brown, RA
    Humar, A
    Covington, E
    Alecock, E
    Paya, CV
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 338 - 339
  • [3] Comparison of valganciclovir and oral ganciclovir for cytomegalovirus prophylaxis in solid organ transplant recipients.
    Kraman, AA
    Hardwick, LL
    Filo, RS
    Govani, MV
    Milgrom, ML
    Tector, AJ
    Pescovitz, MD
    PHARMACOTHERAPY, 2002, 22 (10): : 1370 - 1370
  • [4] Indefinite Valganciclovir Prophylaxis among CMV D+/R- Lung Transplant Patients Is Limited by Breakthrough CMV Infections, Toxicity and Resistance
    Clancy, C.
    Shields, R.
    Toyoda, Y.
    Bhama, J.
    Kwak, E.
    Silveira, F.
    Pilewski, J.
    Crespo, M.
    Nguyen, H.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S61 - S62
  • [5] Factors Associated with the Development of CMV Viremia in High-Risk (D+/R-) Renal Transplant Patients on Valganciclovir Prophylaxis
    Limaye, A.
    Hauser, I.
    Loveless, M.
    Mu, Y.
    Blumberg, E.
    Jardine, A.
    Humar, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 69 - 69
  • [6] A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients
    Juan, R. San
    Yebra, M.
    Lumbreras, C.
    Lopez-Medrano, F.
    Lizasoain, M.
    Meneu, J. C.
    Delgado, J.
    Andres, A.
    Aguado, J. M.
    CLINICAL TRANSPLANTATION, 2009, 23 (05) : 666 - 671
  • [7] Prophylaxis vs Preemptive Therapy for Cytomegalovirus (CMV) Disease in (D+/R-) Liver Transplant Recipients
    Bodro, Marta M.
    Llado, Laura L.
    Sabe, Nuria N.
    Niubo, Jordi J.
    Carratala, Jordi J.
    Baliellas, Carme C.
    Fabregat, Joan J.
    LIVER TRANSPLANTATION, 2011, 17 (06) : S235 - S235
  • [8] Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients
    Humar, A
    Paya, C
    Pescovitz, MD
    Dominguez, E
    Washburn, K
    Blumberg, E
    Alexander, B
    Freeman, R
    Heaton, N
    Mueller, B
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (04) : 644 - 649
  • [9] Population Pharmacokinetics of Ganciclovir after Intravenous Ganciclovir and Oral Valganciclovir Administration in Solid Organ Transplant Patients Infected with Cytomegalovirus
    Caldes, A.
    Colom, H.
    Armendariz, Y.
    Garrido, M. J.
    Troconiz, I. F.
    Gil-Vernet, S.
    Lloberas, N.
    Pou, L.
    Peraire, C.
    Grinyo, J. M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (11) : 4816 - 4824
  • [10] Six-Month Low-Dose Valganciclovir Prophylaxis in Cytomegalovirus D+/R- Kidney Transplant Patients Receiving Thymoglobulin Induction
    Luan, F. L.
    TRANSPLANTATION PROCEEDINGS, 2013, 45 (01) : 175 - 177
1234